December 5th 2024
Cambrex will provide Lilly’s biotech collaborators with accelerated access to clinical development capabilities.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Biopharmaceutical Excipients: Everything You Need to Know
April 19th 2024This article represents a comprehensive exploration about biopharmaceutical excipients, exploring their multifaceted classification, active role in drug formulation processes, inherent challenges, and upcoming advancements poised to revolutionize the drug formulation and its efficacy for patient welfare.
Charles River Enters pDNA Manufacturing Deals with Axovia Therapeutics and Ship of Theseus
April 10th 2024In back-to-back deals, Charles River will offer plasmid DNA manufacturing services for a gene therapy under development by Axovia Therapeutics and for a lead candidate being developed by Ship of Theseus.